Company / Capital Expenditures
Akebia Therapeutics, Inc. Capital Expenditures History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$291.0K
FY2025
5-year range
$0 / $6.7M
FY2021-FY2025
Trend
+781.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +782% YoY in FY2025, a notable deviation from the 8-year average annual change of +1846%.
Based on SEC 10-K filings.
$291,000 in FY2025 with a 10-year CAGR of +31.4%.
Improved from $0 to $291,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +36.7%
- 5-Year CAGR
- -28.9%
- 10-Year CAGR
- +31.4%
Key checks
Key Insights
- 5-year CAGR of -28.9%, indicating a declining trend.
- In FY2025, capital expenditures increased 781.8% year-over-year.
- Peak capital expenditures was recorded in FY2021.
- Lowest capital expenditures in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $291.0K | +781.8% |
| FY2024 | $33.0K | - |
| FY2023 | $0 | -100.0% |
| FY2022 | $114.0K | -98.3% |
| FY2021 | $6.7M | +314.4% |
| FY2020 | $1.6M | -1.0% |
| FY2019 | $1.6M | -39.1% |
| FY2018 | $2.7M | +13910.5% |
| FY2015 | $19.0K | +0.0% |
| FY2014 | $19.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026